Naranjo, Francisco, JR. .

HRN: 26-81-15  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/17/2025
CO-AMOXICLAV 625MG (TAB)
03/17/2025
03/19/2025
PO
625mg
TID
Infected Diabetic Foot
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: